AP137A - Pharmaceutical composition for the treatment of protozoal diseases particulary of trypanosomiasis, comprising D-carnitine or an acyl derivative of D-carnitine. - Google Patents
Pharmaceutical composition for the treatment of protozoal diseases particulary of trypanosomiasis, comprising D-carnitine or an acyl derivative of D-carnitine. Download PDFInfo
- Publication number
- AP137A AP137A APAP/P/1990/000180A AP9000180A AP137A AP 137 A AP137 A AP 137A AP 9000180 A AP9000180 A AP 9000180A AP 137 A AP137 A AP 137A
- Authority
- AP
- ARIPO
- Prior art keywords
- carnitine
- treatment
- trypanosomiasis
- pharmaceutical composition
- protozoal diseases
- Prior art date
Links
- PHIQHXFUZVPYII-LURJTMIESA-N (S)-carnitine Chemical compound C[N+](C)(C)C[C@@H](O)CC([O-])=O PHIQHXFUZVPYII-LURJTMIESA-N 0.000 title claims abstract description 37
- 238000011282 treatment Methods 0.000 title claims abstract description 26
- 125000002252 acyl group Chemical group 0.000 title claims abstract description 16
- 229960004203 carnitine Drugs 0.000 title claims abstract description 15
- 201000010099 disease Diseases 0.000 title claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 15
- 201000002311 trypanosomiasis Diseases 0.000 title claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- -1 acetyl Chemical compound 0.000 claims abstract description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 4
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 230000000590 parasiticidal effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 208000000230 African Trypanosomiasis Diseases 0.000 description 8
- 206010001935 American trypanosomiasis Diseases 0.000 description 8
- 208000009182 Parasitemia Diseases 0.000 description 7
- 208000030852 Parasitic disease Diseases 0.000 description 7
- 241000223109 Trypanosoma cruzi Species 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 208000024699 Chagas disease Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 244000045947 parasite Species 0.000 description 6
- JXXCENBLGFBQJM-RGMNGODLSA-N (3s)-3-hydroxy-4-(trimethylazaniumyl)butanoate;hydrochloride Chemical compound [Cl-].C[N+](C)(C)C[C@@H](O)CC(O)=O JXXCENBLGFBQJM-RGMNGODLSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 241000223091 Trypanosoma lewisi Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 241000223104 Trypanosoma Species 0.000 description 4
- 241000223105 Trypanosoma brucei Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- YCGRRHTUOIMIST-JTQLQIEISA-N (3S)-3-hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]hexanoate Chemical compound C(CC)(=O)[C@@](O)(C[N+](C)(C)C)CC([O-])=O YCGRRHTUOIMIST-JTQLQIEISA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- PHIQHXFUZVPYII-UHFFFAOYSA-N carnitine Chemical compound C[N+](C)(C)CC(O)CC([O-])=O PHIQHXFUZVPYII-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000016491 infection by Trypanosoma rhodesiense Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CULUWZNBISUWAS-UHFFFAOYSA-N Benznidazole Chemical compound [O-][N+](=O)C1=NC=CN1CC(=O)NCC1=CC=CC=C1 CULUWZNBISUWAS-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000008771 Lymphadenopathy Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- ARFHIAQFJWUCFH-IZZDOVSWSA-N Nifurtimox Chemical compound CC1CS(=O)(=O)CCN1\N=C\C1=CC=C([N+]([O-])=O)O1 ARFHIAQFJWUCFH-IZZDOVSWSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000013228 adenopathy Diseases 0.000 description 2
- 229960004001 benznidazole Drugs 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 208000029080 human African trypanosomiasis Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229960002644 nifurtimox Drugs 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000009291 secondary effect Effects 0.000 description 2
- 201000002612 sleeping sickness Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 2
- 229960005314 suramin Drugs 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000000289 Esophageal Achalasia Diseases 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 241000257324 Glossina <genus> Species 0.000 description 1
- 241001502121 Glossina brevipalpis Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000258937 Hemiptera Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 206010048961 Localised oedema Diseases 0.000 description 1
- JCYZMTMYPZHVBF-UHFFFAOYSA-N Melarsoprol Chemical compound NC1=NC(N)=NC(NC=2C=CC(=CC=2)[As]2SC(CO)CS2)=N1 JCYZMTMYPZHVBF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030136 Oesophageal achalasia Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 241001124072 Reduviidae Species 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241001414833 Triatoma Species 0.000 description 1
- 241001210412 Triatominae Species 0.000 description 1
- 241001442399 Trypanosoma brucei gambiense Species 0.000 description 1
- 206010044708 Trypanosomal infections Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000005180 acute myocarditis Diseases 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000574 ganglionic effect Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000004840 megacolon Diseases 0.000 description 1
- 201000005563 megaesophagus Diseases 0.000 description 1
- 229960001728 melarsoprol Drugs 0.000 description 1
- 201000011475 meningoencephalitis Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000020470 nervous system symptom Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical class NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000008280 toxic mechanism Effects 0.000 description 1
- UULSDCUWMKTMND-UHFFFAOYSA-N tryparsamide Chemical compound NC(=O)CNC1=CC=C([As](O)(O)=O)C=C1 UULSDCUWMKTMND-UHFFFAOYSA-N 0.000 description 1
- 229950000574 tryparsamide Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT8947916A IT1231944B (it) | 1989-05-05 | 1989-05-05 | Composizione farmaceutica per il trattamento di protozoosi, particolarmente della tripasonomiasi comprendente d-carnitina o un alcanoilderivato della d-carnitina |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9000180A0 AP9000180A0 (en) | 1990-07-31 |
| AP137A true AP137A (en) | 1991-08-05 |
Family
ID=11263328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1990/000180A AP137A (en) | 1989-05-05 | 1990-05-02 | Pharmaceutical composition for the treatment of protozoal diseases particulary of trypanosomiasis, comprising D-carnitine or an acyl derivative of D-carnitine. |
Country Status (5)
| Country | Link |
|---|---|
| AP (1) | AP137A (it) |
| GB (1) | GB2230953B (it) |
| IT (1) | IT1231944B (it) |
| OA (1) | OA09832A (it) |
| ZA (1) | ZA903352B (it) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1254136B (it) * | 1992-01-16 | 1995-09-08 | Sigma Tau Ind Farmaceuti | Esteri di acil carnitine con alcooli alifatici a lunga catena e composizioni farmaceutiche che li contengono, ad attivita' antimicotica. |
| IT1254135B (it) * | 1992-01-16 | 1995-09-08 | Sigma Tau Ind Farmaceuti | Esteri di acil carnitine con alcooli alifatici a lunga catena e composizioni farmaceutiche che li contengono, ad attivita' antibatterica. |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1474424A (en) * | 1973-09-26 | 1977-05-25 | Kawashima Y | Pharmaceutical composition for treating diabetic ketoacidosis |
| US4871773A (en) * | 1986-06-04 | 1989-10-03 | Avantgarde S.P.A. | N-alkylamides of D(+)-carnitine having antibacterial activity, process for their preparation and pharmaceutical and cosmetic compositions containing same |
| WO1989011276A1 (fr) * | 1988-05-26 | 1989-11-30 | Bernardini, Attilio | Acyl-carnitine pour le traitement et la prevention d'infections virales |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2903579A1 (de) * | 1978-02-03 | 1979-08-09 | Sigma Tau Ind Farmaceuti | Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel |
| DE2903558C2 (de) * | 1978-02-03 | 1994-09-01 | Sigma Tau Ind Farmaceuti | Verwendung von L-Carnitin |
| IT1156769B (it) * | 1978-05-25 | 1987-02-04 | Sigma Tau Ind Farmaceuti | Applicazione terapeutica della carnitina e di altri acil derivati della carnitina |
| IT1206954B (it) * | 1979-02-12 | 1989-05-17 | Sigma Tau Ind Farmaceuti | Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche |
| JPS5661314A (en) * | 1979-10-24 | 1981-05-26 | Otsuka Pharmaceut Factory Inc | Preventive against side-effect for dialytic patient |
| JPS57126420A (en) * | 1981-01-26 | 1982-08-06 | Eiji Murakami | Drug for digestive organ |
| IT1142934B (it) * | 1981-11-06 | 1986-10-15 | Sigma Tau Ind Farmaceuti | Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene |
-
1989
- 1989-05-05 IT IT8947916A patent/IT1231944B/it active
-
1990
- 1990-05-02 AP APAP/P/1990/000180A patent/AP137A/en active
- 1990-05-03 ZA ZA903352A patent/ZA903352B/xx unknown
- 1990-05-04 OA OA59786A patent/OA09832A/en unknown
- 1990-05-04 GB GB9010190A patent/GB2230953B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1474424A (en) * | 1973-09-26 | 1977-05-25 | Kawashima Y | Pharmaceutical composition for treating diabetic ketoacidosis |
| US4871773A (en) * | 1986-06-04 | 1989-10-03 | Avantgarde S.P.A. | N-alkylamides of D(+)-carnitine having antibacterial activity, process for their preparation and pharmaceutical and cosmetic compositions containing same |
| WO1989011276A1 (fr) * | 1988-05-26 | 1989-11-30 | Bernardini, Attilio | Acyl-carnitine pour le traitement et la prevention d'infections virales |
Also Published As
| Publication number | Publication date |
|---|---|
| GB9010190D0 (en) | 1990-06-27 |
| IT1231944B (it) | 1992-01-16 |
| ZA903352B (en) | 1991-02-27 |
| IT8947916A0 (it) | 1989-05-05 |
| OA09832A (en) | 1994-04-15 |
| GB2230953B (en) | 1993-03-24 |
| AP9000180A0 (en) | 1990-07-31 |
| GB2230953A (en) | 1990-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003131876A (ru) | Композиции n-ацетилцистеина и способы лечения и профилактики токсичности лекарственных средств | |
| JPH0643299B2 (ja) | 薬剤療法 | |
| CA2664935A1 (en) | Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c | |
| SK281982B6 (sk) | Použitie zlúčenín gabapentínu na výrobu liečiva | |
| RU2004131214A (ru) | Способы лечения когнитивных расстройств | |
| Mimaki et al. | Antiepileptic effect and serum levels of zonisamide in epileptic patients with refractory seizures | |
| AP137A (en) | Pharmaceutical composition for the treatment of protozoal diseases particulary of trypanosomiasis, comprising D-carnitine or an acyl derivative of D-carnitine. | |
| US5011841A (en) | Treatment of depression | |
| JPH0616570A (ja) | 心臓血管障害の処置のためのａｃｅ阻害剤を配合するｌ−カルニチンまたはアシル−ｌ−カルニチンを含む医薬組成物 | |
| US20250325503A1 (en) | New use of n,n-bis-2-mercaptoethyl isophthalamide | |
| AU5160293A (en) | Arsenic medicaments for the treatment of chronic fatigue syndrome | |
| Bharani | Sexual dysfunction after gemfibrozil | |
| US8952059B2 (en) | Acetyl L-carnitine for the preparation of a medicament for the prevention of painful peripheral neuropathy in patients with type 2 diabetes | |
| AU742013B2 (en) | Composition comprising ketanserin and L-carnitine or an alkanoyl L-carnitine for the treatment of CRPS | |
| KR0137009B1 (ko) | L-카르니틴및아실l-카르니틴의원발성정충무력과소증치료용조성물 | |
| AU642045B2 (en) | Pharmaceutical compositions for use in treating parkinson's disease | |
| US4663345A (en) | Etodolac for treatment of gout | |
| Miller | Neuromuscular complications of human immunodeficiency virus infection and antiretroviral therapy | |
| EP0006752A1 (en) | Compositions for the treatment of chronic trypanosomiasis infections | |
| KR920003579B1 (ko) | 혈중 지질 조성을 개선시키기 위한 제약 조성물 | |
| Morton et al. | Cortical blindness after nifedipine treatment | |
| Stinson et al. | Ventricular asystole and overdose with atenolol | |
| PT99962B (pt) | Utilizacao de um medicamento anti-depressivo | |
| GILLIGAN et al. | ENTERIC‐COATED L‐DOPA (PRODOPA) A NEW APPROACH TO L‐DOPA THERAPY IN PARKINSON'S DISEASE | |
| JPH0586043A (ja) | 医薬組成物 |